SuperworthBioNexus Gene Lab BGLC
- Market cap
- $3.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.1×
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- $3.1M
- −67% on a year ago
- Net margin
- −82.4%
- Free cash flow yield
- −24.5%
BioNexus Gene Lab trades at 1.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $3.1M over the last twelve months, down 67% on a year earlier with a −82% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.6M−1% | $2.3M−20% | $2.4M+0% | $2M−23% | $2.6M+3% | $2.5M+11% | $2.1M−10% | $2.3M+15% | $2.5M−3% | $483.8K−81% | $22.8K−99% | $76.2K−97% | |
| Cost of revenue | $2.2M−3% | $2M−20% | $2M+0% | $1.7M−24% | $2.3M+5% | $2.2M+10% | $1.8M−11% | $1.9M+12% | $2.2M−6% | $487.7K−78% | $23.6K−99% | $63.2K−97% |
| Gross profit | $354.3K+18% | $266.6K−21% | $365K−1% | $288.7K−15% | $326.5K−8% | $309.2K+16% | $343.5K−6% | $368K+28% | $377.7K+16% | −$4K | −$790 | $13K−97% |
| R&D | n/a | n/a | $11.5K | $8.2K | $10.4K | $17.4K | $12.1K+6% | $12.6K+53% | $14.9K+43% | $11.1K−36% | $14.5K+19% | $13.7K+9% |
| SG&A | $3.1M+636% | n/a | $469.7K−13% | $695.3K−14% | $2M−34% | $660.8K | $932.6K+99% | $1.1M+62% | $997.3K−51% | $216.7K−67% | $380.4K−59% | $334.5K−70% |
| −$2.5M+3777% | $257.8K | −$79K+56% | $259.2K | −$1.3M−47% | −$416.2K | −$618.4K+683% | −$611.3K | −$702.5K−48% | −$1M+148% | −$540.5K−13% | −$282.4K−54% | |
| Interest expense | $4.3K+106% | $4.2K−12% | $4.7K+91% | $4.5K+47% | $6.2K+45% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$2.5M+3664% | $253.6K | −$83.7K+58% | $254.7K | −$1.3M−47% | −$422K | −$623.3K+645% | −$616.2K | −$709K−47% | −$1M+146% | −$543.6K−13% | −$286.5K−54% |
| $76.4K+656% | −$97.9K+30% | −$20.1K | $55.6K+248% | $1.6K−98% | −$80.7K−18% | $0 | $0 | $0 | $0 | n/a | $0 | |
| Net income | −$2.6M+3271% | $308.5K | −$103.8K+50% | $199.1K | −$1.3M−48% | −$348.3K | −$623.3K+501% | −$616.2K | −$709K−47% | −$1M+198% | −$543.6K−13% | −$286.5K−54% |
| n/a | n/a | −$0.01 | $0.11 | −$0.75 | n/a | −$0.35+5683% | −$0.34 | −$0.40−47% | −$0.51 | −$0.23−35% | −$0.12−66% | |
| n/a | n/a | 17.7M+1120% | 1.8M−90% | 1.8M | n/a | 1.8M−90% | 1.8M+2% | 1.8M+0% | n/a | 2.4M+35% | 2.4M+35% |
Revenue: Q1 FY18: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY18: 6 months less the 3 months printed beside them.
Income tax: Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 12 periods, Q1 FY18 to Q2 FY23: quarter's net income to common over its shares, to the cent. Q4 FY25: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'.
Diluted shares: 3 periods, Q4 FY18 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20 and Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest BioNexus Gene Lab's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BGLCBioNexus Gene Lab | $3.5M | n/m | 175× | 1.1× | −67% | −82.4% | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on BioNexus Gene Lab
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .